MindBio Therapeutics to Raise Up to $1.1 Million in Private Placement
November 26, 2025 — Leads & Copy — MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6) will conduct a non-brokered private placement to raise gross proceeds up to $1,100,000.
The biotechnology company will offer up to 2,070,000 units (each, an “AI Unit”) at a price of $0.40 per AI Unit for gross proceeds of up to $828,000 pursuant to the accredited investor exemption under Section 2.3 of National Instrument 45-106 – Prospectus Exemptions. The company will also offer up to 680,000 units (each, a “LIFE Unit”) at a price of $0.40 per LIFE Unit for gross proceeds of up to $272,000 pursuant to the listed issuer financing exemption under Part 5A of NI- 45-106.
Each AI Unit will consist of one common share of the company and one share purchase warrant. Each Warrant will entitle the holder to acquire an additional common share of the company at a price of $0.70 for a period of thirty-six months following closing of the Offering, subject to accelerated expiry in the event the closing price of the Shares on the Canadian Securities Exchange exceeds $1.00 for ten consecutive trading days. Each LIFE Unit will consist of one Share and one-half-of-one Warrant.
The company intends to use the net proceeds from the Offering to advance development of its prediction technologies in drug and alcohol intoxication detection for consumer and enterprise purposes in mental health, and for general working capital purposes.
An offering document related to the Offering will be made available under the company’s profile on SEDAR+ at www.sedarplus.ca and on the company’s website. Prospective investors should read this offering document before making an investment decision. In connection with completion of the Offering, the company will pay finders’ fees to eligible third-parties who have introduced subscribers to the Offering.
All securities issued in connection with the Accredited Investor Exemption will be subject to restrictions on resale for a period of four-months-and-one-day in accordance with applicable securities laws. All securities issued in connection with the Listed Issuer Financing Exemption will not be subject to a hold period.
If the Offering is completed in full, the company will have issued more than one-hundred percent of its existing share capital. As a result, the policies of the Canadian Securities Exchange require the company to obtain shareholder approval for the Offering. The company intends to obtain shareholder approval by obtaining the written-consent of the majority of its outstanding shares.
If shareholder approval is not received, the company may elect to reduce the size of the Offering or not to proceed with the Offering at all. Completion of the Offering remains subject to receipt of regulatory approvals.
The company also reported the final completion of clinical software development has occurred in respect to the previously announced (14 October, 2025), acquisition of software and 87,500 post consolidation warrants have been issued to the software vendor with an exercise price of 50c per warrant in satisfaction of completion of those services.
The company will use the core aspects of the software for data collection and analysis with its work in speech and intoxication detection for deployment in enterprise scenarios. The company intends to build its first prototype of its intoxication detection technology for use in enterprise environments within the next 4-6 months.
MindBio Therapeutics Corp. is a clinical-stage biotechnology company headquartered in Vancouver, British Columbia, that for several years has been conducting clinical trials and is focused on developing novel treatments for mental health disorders and health prediction technologies using AI and machine learning.
For further information, please contact Justin Hanka, Chief Executive Officer at 61 433140886 or justin@mindbiotherapeutics.com
Source: MindBio Therapeutics Corp.
Share this story:
